Freddie C. Hamdy, MD of University of Oxford gives his take on which choice would warrant over the others when it comes to their difference in side effects for patients with metastatic prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.